Form 4: Revance Therapeutics Executive Sells Shares to Cover Tax Obligations

A Revance Therapeutics executive sold 3,908 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• David Hollander, CMO & Global Therapeutics Lead at Revance Therapeutics, sold 3,908 shares of common stock on November 18, 2024.
• The sale was executed at a weighted average price of $4.17 per share.
• This transaction was not a discretionary trade but was mandated by the company's sell-to-cover agreement to satisfy tax withholding obligations.
• The shares were sold to cover taxes associated with the vesting of restricted stock units granted on October 17, 2022.
• The restricted stock units vest in equal installments over a four-year period.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and tax obligations, with no indication of positive or negative sentiment.

Industry Context

This is a routine transaction related to executive compensation and tax obligations, common in publicly traded companies. It does not indicate any change in the company's performance or outlook.

Comparison to Industry Standards

• Sell-to-cover transactions are a standard practice for executives receiving equity compensation in publicly traded companies.
• The vesting schedule of four years is also a common practice for restricted stock units.
• Similar transactions are regularly reported by executives at comparable biotech companies.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.

Key Dates

Keywords

Revance Therapeutics, insider trading, Form 4, stock sale, tax obligations, restricted stock units, executive compensation, RVNC